05
Dec 2014
Share This
0 Comments
stand up to cancer

Cancer Stem Cell Research Dream Team: A Call for Ideas

Posted by

The best and the brightest are teaming up against cancer.

In October, Stand Up To Cancer Canada (SU2C Canada), with support from the Cancer Stem Cell Consortium (CSCC), Genome Canada and the Canadian Institutes of Health Research (CIHR), announced a $10.6 million SU2C Canada Cancer Stem Cell Dream Team Research funding opportunity.

SU2C Canada is an innovative funding initiative created in July 2014 to accelerate advances in cancer research. Sharing a common mission with the U.S.- based Stand Up to Cancer, active since 2008, SU2C Canada provides grants to multidisciplinary groups of scientists, called Dream Teams, who work collaboratively to develop treatments for cancer patients.

The American Association for Cancer Research International – Canada (AACR International – Canada), the Scientific Partner of SU2C Canada, issued a Call for Ideas inviting the Canadian research community to assemble into a Cancer Stem Cell Dream Team. Scientists from across the country are invited to submit  a Letter of Intent by December 8th.. Complete proposals must be sent by April 27th, 2015. Please click here for information on eligibility and submission requirements.

The qualifying Dream Team will receive approximately $10.6 million over a four-year term from CSCC, through Genome Canada and CIHR. Additional funds up to $3 million over four years from Ontario Institute for Cancer Research (OICR) will be available for clinical trials conducted in Ontario.

The research proposals will be reviewed oby the SU2C Canada Scientific Advisory Committee (CSAC), co-chaired by Nobel Laureate Dr. Phillip A. Sharp, Institute Professor at the Massachusetts Institute of Technology (MIT), and Dr. Alan Bernstein, President & CEO of the Canadian Institute for Advanced Research, and Chair of the Board of Directors for the Canadian Stem Cell Foundation.

“Dr. Sharp and I are very pleased to launch this collaborative approach to cancer research with an emphasis on working across disciplines and institutional lines to deliver new treatments in an accelerated timeframe,” says Dr. Bernstein in the SU2C Canada press release. “We look forward to reviewing extraordinary approaches to cancer research assembled by the best and brightest minds, and to selecting the best possible science that Canada has to offer.”

Leave a Reply

Your email address will not be published. Required fields are marked *

If you are a human, do not fill out this field